EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

Li Lu iD, Mingqi Xie iD, Bo Yang, Wen-Bin Zhao iD, Ji Cao iD

Science Advances · 23.02.2024 · 10 (8)

DOI: 10.1126/sciadv.adj6251 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Advances, erschienen am 23.02.2024. Verfasst von Li Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted therapy for cancer that has demonstrated notable potential in clinical applications. However, severe adverse effects limit the clinical application of this therapy and are mainly caused by uncontrollable activation of CAR-T cells, including excessive immune response activation due to unregulated CAR-T cell action time, as well as toxicity resulting from improper spatial localization. Therefore, to enhance controllability and safety, a control module for CAR-T cells is proposed. Synthetic biology based on genetic engineering techniques is being used to construct artificial cells or organisms for specific purposes. This approach has been explored in recent years as a means of achieving controllability in CAR-T cell therapy. In this review, we summarize the recent advances in synthetic biology methods used to address the major adverse effects of CAR-T cell therapy in both the temporal and spatial dimensions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveCell- and Tissue-Based Therapy

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
  • Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
  • Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, Hangzhou, Zhejiang 310024, China.
  • School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China.
  • Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China.

ORCID-Profile: Li Lu, Mingqi Xie, Wen-Bin Zhao, Ji Cao

Zitieren

APA

Lu, L., Xie, M., Yang, B., Zhao, W. B., & Cao, J. (2024). Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Science Advances, 10(8). https://doi.org/10.1126/sciadv.adj6251

Vancouver

Lu L, Xie M, Yang B, Zhao WB, Cao J. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Science Advances. 2024;10(8). doi:10.1126/sciadv.adj6251

BibTeX
@article{Lu2024,
  author = {Lu, Li and Xie, Mingqi and Yang, Bo and Zhao, Wen-Bin and Cao, Ji},
  title = {Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {8},
  doi = {10.1126/sciadv.adj6251}
}
Kostenlos starten →